| Canagliflozin and renal outcomes in type 2 diabetes and nephropathy V Perkovic, MJ Jardine, B Neal, S Bompoint, HJL Heerspink, ... New England journal of medicine 380 (24), 2295-2306, 2019 | 5144 | 2019 |
| Dapagliflozin in patients with chronic kidney disease HJL Heerspink, BV Stefánsson, R Correa-Rotter, GM Chertow, T Greene, ... New England Journal of Medicine 383 (15), 1436-1446, 2020 | 3671 | 2020 |
| Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention RT Gansevoort, R Correa-Rotter, BR Hemmelgarn, TH Jafar, ... The Lancet 382 (9889), 339-352, 2013 | 2391 | 2013 |
| Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis CS Fox, K Matsushita, M Woodward, HJG Bilo, J Chalmers, ... The Lancet 380 (9854), 1662-1673, 2012 | 1267 | 2012 |
| Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications HJL Heerspink, BA Perkins, DH Fitchett, M Husain, DZI Cherney Circulation 134 (10), 752-772, 2016 | 1234 | 2016 |
| Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease D De Zeeuw, T Akizawa, P Audhya, GL Bakris, M Chin, H Christ-Schmidt, ... New England Journal of Medicine 369 (26), 2492-2503, 2013 | 1049 | 2013 |
| Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy A Levin, M Tonelli, J Bonventre, J Coresh, JA Donner, AB Fogo, CS Fox, ... The Lancet 390 (10105), 1888-1917, 2017 | 922 | 2017 |
| Dapagliflozin a glucose‐regulating drug with diuretic properties in subjects with type 2 diabetes HJ Lambers Heerspink, D De Zeeuw, L Wie, B Leslie, J List Diabetes, Obesity and Metabolism 15 (9), 853-862, 2013 | 893 | 2013 |
| Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease … BC Astor, K Matsushita, RT Gansevoort, M Van Der Velde, M Woodward, ... Kidney international 79 (12), 1331-1340, 2011 | 805 | 2011 |
| SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis BL Neuen, T Young, HJL Heerspink, B Neal, V Perkovic, L Billot, ... The lancet Diabetes & endocrinology 7 (11), 845-854, 2019 | 782 | 2019 |
| Glomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment L Tonneijck, MHA Muskiet, MM Smits, EJ Van Bommel, HJL Heerspink, ... Journal of the American Society of Nephrology 28 (4), 1023-1039, 2017 | 733 | 2017 |
| Age and association of kidney measures with mortality and end-stage renal disease SI Hallan, K Matsushita, Y Sang, BK Mahmoodi, C Black, A Ishani, ... Jama 308 (22), 2349-2360, 2012 | 705 | 2012 |
| Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial O Mosenzon, SD Wiviott, A Cahn, A Rozenberg, I Yanuv, EL Goodrich, ... The lancet Diabetes & endocrinology 7 (8), 606-617, 2019 | 679 | 2019 |
| KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease IH de Boer, ML Caramori, JCN Chan, HJL Heerspink, C Hurst, K Khunti, ... Kidney international 98 (4), S1-S115, 2020 | 583 | 2020 |
| Multinational assessment of accuracy of equations for predicting risk of kidney failure: a meta-analysis N Tangri, ME Grams, AS Levey, J Coresh, LJ Appel, BC Astor, G Chodick, ... Jama 315 (2), 164-174, 2016 | 581 | 2016 |
| Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials HJL Heerspink, T Ninomiya, S Zoungas, D de Zeeuw, DE Grobbee, ... The Lancet 373 (9668), 1009-1015, 2009 | 544 | 2009 |
| Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial HJL Heerspink, HH Parving, DL Andress, G Bakris, R Correa-Rotter, ... The Lancet 393 (10184), 1937-1947, 2019 | 506 | 2019 |
| Association of vitamin D status with arterial blood pressure and hypertension risk: a mendelian randomisation study KS Vimaleswaran, A Cavadino, DJ Berry, R Jorde, AK Dieffenbach, C Lu, ... The lancet Diabetes & endocrinology 2 (9), 719-729, 2014 | 445 | 2014 |
| Canagliflozin slows progression of renal function decline independently of glycemic effects HJL Heerspink, M Desai, M Jardine, D Balis, G Meininger, V Perkovic Journal of the American Society of Nephrology 28 (1), 368-375, 2017 | 387 | 2017 |
| Dietary salt intake and mortality in patients with type 2 diabetes EI Ekinci, S Clarke, MC Thomas, JL Moran, K Cheong, RJ MacIsaac, ... Diabetes care 34 (3), 703-709, 2011 | 387 | 2011 |
